Natural history of grade 1 ascites in patients with liver cirrhosis

Theodorakopoulos, Theodoros; Kalafateli, Maria; Kalambokis, Georgios; Samonakis, Dimitrios; Αγγελετοπούλου, Ιωάννα; Tsolias, Chrysostomos; Mantaka, Aikaterini; Tselekouni, Paraskevi; Vourli, Georgia; Assimakopoulos, Stelios F.; Gogos, Charalampos; Thomopoulos, Konstantinos; Milionis, Haralampos; Triantos, Christos

doi:10.20524/aog.2020.0553

Cited by 4 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical classification of the CTP score is as follows: 5 to 6 points are considered as class A (well-compensated cirrhosis), 7 to 9 points are class B (significant functional compromise) and 10 to 15 points are class C (decompensated cirrhosis) [ 21 ]. The interpretation of ascites was determined based on the amount of abdominal fluid: grade 1 ascites detected via ultrasound; grade 2 ascites defined based on relative abdominal distension; and grade 3 ascites with compelling abdominal extension [ 22 ]. The West Haven Criteria were used for grading the severity of hepatic encephalopathy [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

et al. 2023

View full text Add to dashboard Cite

Hypocalcemia is a common condition in liver cirrhosis and is associated with the severity of SARS-CoV-2 infection. However, there is a lack of data demonstrating the prognostic value of hypocalcemia in COVID-19 patients with cirrhosis. This study aimed to evaluate the prognostic value of hypocalcemia for COVID-19 severity, mortality and its associations with abnormal liver function parameters. We selected 451 COVID-19 patients in this retrospective study and compared the laboratory findings of 52 COVID-19 patients with cirrhosis to those of 399 COVID-19 patients without cirrhosis. Laboratory tests measuring albumin-corrected total serum calcium were performed on admission, and the levels were monitored during hospitalization. The total serum calcium levels were significantly lower in cirrhosis cases (2.16 mmol/L) compared to those without cirrhosis (2.32 mmol/L). Multivariate analysis showed that hypocalcemia in COVID-19 patients with cirrhosis was a significant predictor of in-hospital mortality, with an OR of 4.871 (p < 0.05; 95% CI 1.566–15.146). ROC analysis showed the AUC value of total serum calcium was 0.818 (95% CI 0.683–0.953, p < 0.05), with a sensitivity of 88.3% and a specificity of 75%. The total serum calcium levels showed a significant negative correlation with the Child–Turcette–Pugh score (r = −0.400, p < 0.05). Hypocalcemia on admission was a significant prognostic factor of disease progression in COVID-19 patients with cirrhosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Decompensated cirrhosis was characterised by ascites, hepatic encephalopathy or variceal haemorrhage. The evaluation of ascites was based on the volume of abdominal fluid: mild ascites detected by ultrasound; moderate ascites described by proportional abdominal distension; large ascites with compelling abdominal extension [ 18 ]. The severity of hepatic encephalopathy was classified according to the West Haven Criteria [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study

et al. 2022

View full text Add to dashboard Cite

Patients with cirrhosis are vulnerable to hepatic decompensation events and death following COVID-19 infection. Therefore, primary vaccination with COVID-19 vaccines is fundamental to reducing the risk of COVID-19 related deaths in patients with cirrhosis. However, limited data are available about the effectiveness of mRNA vaccines compared to other vaccines. The aim of our study was to investigate the efficacy of mRNA vaccines versus other vaccines in cirrhosis. In this retrospective study, we compared clinical characteristics and vaccine effectiveness of 399 COVID-19 patients without cirrhosis (GROUP A) to 52 COVID-19 patients with cirrhosis (GROUP B). 54 hospitalised cirrhosis controls without COVID-19 (GROUP C) were randomly sampled 1:1 and matched by gender and age. Of the cirrhosis cases, we found no difference (p = 0.76) in mortality rates in controls without COVID-19 (11.8%) compared to those with COVID-19 (9.6%). However, COVID-19 patients with cirrhosis were associated with higher rates of worsening hepatic encephalopathy, ascites and esophageal varices. Patients with cirrhosis receiving mRNA vaccines had significantly better survival rates compared to viral vector or inactivated vaccines. Primary vaccination with the BNT162b2 vaccine was the most effective in preventing acute hepatic decompensating events, COVID-19 infection requiring hospital admission and in-hospital mortality.

show abstract

Asia–Pacific association for study of liver guidelines on management of ascites in liver disease

Singh

Mehtani

et al. 2023

Hepatol Int

View full text Add to dashboard Cite

Natural history of grade 1 ascites in patients with liver cirrhosis

Cited by 4 publications

References 34 publications

Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study

Asia–Pacific association for study of liver guidelines on management of ascites in liver disease

Contact Info

Product

Resources

About